Pseudovirus News and Research

RSS

Effective neutralization of SARS-CoV-2 by synthetic nanobodies targeting the spike protein

In their recent bioRxiv paper, a multinational group of researchers reported rapid isolation and characterization of nanobodies from a synthetic library (known as sybodies) that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein – with a strikingly high neutralization ability.

24 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

SARS-CoV-2 mutated spike proteins show variations in cell entry

A new study by Japanese scientists published on the preprint server bioRxiv* in June 2020 shows that the D614g mutation in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein can enhance the infectivity of the virus while leaving it vulnerable to neutralization by antibodies.

17 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Antibody cocktail is being tested in human COVID-19 trials

Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which both antibodies bind the viral target simultaneously, a resultant antibody cocktail is being tested in human trials.

16 Jun 2020

Synthetic nanobodies potent neutralizers for SARS-CoV-2

Researchers at the Chinese Academy of Sciences report the generation of potent synthetic nanobodies that selectively and efficiently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus.

11 Jun 2020

Scientists investigate immune responses to SARS-CoV-2 spike immunogens

The coronavirus pandemic is actively spreading across the globe, with millions of people infected. Amid the global health crisis, scientists race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 Jun 2020

Study finds very low level of SARS-CoV-2 in two San Francisco Bay areas

A new study published on the preprint server medRxiv in May 2020 reports a very low prevalence of antibodies in two separate populations living in the San Francisco Bay Area.

26 May 2020

Producing virus-specific antibodies after COVID-19

In order to design effective vaccines for COVID-19, we need to understand our immune responses. News-Medical speaks to Professor Chen Dong to find out more.

21 May 2020

Does cholesterol play a role in COVID-19?

A new study published on the preprint server bioRxiv in May 2020 suggests that the strikingly increased mortality in COVID-19 patients who are either old or also have high blood pressure, diabetes, cardiovascular disease is due to high tissue cholesterol levels. It also indicates the role of a healthy diet, by showing that polyunsaturated fatty acids (PUFA) in blood oppose the effects of cholesterol and thus the risk for severe COVID-19 symptoms.

12 May 2020

Patients recently recovered from COVID-19 produce virus-specific antibodies

Most newly discharged patients who recently recovered from COVID-19 produce virus-specific antibodies and T cells, suggests a study published on May 3rd in the journal Immunity, but the responses of different patients are not all the same.

5 May 2020

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

A new study reports the induction of high levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the current pandemic of COVID-19. This promising finding was reported on the preprint server bioRxiv on April 2020.

26 Apr 2020

UK diagnostics firm develops rapid test to fight against COVID-19

A team of UK biotech experts are close to delivering a sophisticated and affordable testing technology that will complement the simple binary COVID-19 tests currently in use.

3 Apr 2020

ASU Biodesign researchers develop more potent, safer plant-based Zika vaccine

The worldwide Zika threat first emerged in 2015, infecting millions as it swept across the Americas. It struck great fear in pregnant women, as babies born with severe brain birth defects quickly overburdened hospitals and public health care systems.

9 Aug 2017

UNC researchers identify a type of vaginal bacteria that can protect women from HIV

Researchers at the University of North Carolina at Chapel Hill have identified a type of vaginal bacteria within the mucus of the female reproductive system that can protect women from HIV as well as other sexually transmitted infections.

9 Oct 2015

Cervicovaginal mucus effectively traps HIV particles

HIV particles are effectively trapped by the cervicovaginal mucus from women who harbor a particular vaginal bacteria species, Lactobacillus crispatus. The findings, published this week in mBio, an online open-access journal of the American Society for Microbiology, could lead to new ways to reduce or block vaginal transmission of HIV and other sexually transmitted infections (STIs).

7 Oct 2015

Bio-Bridge Science granted Japanese patent covering use of papilloma pseudovirus

Bio-Bridge Science, Inc., a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Japanese Patent Office has granted claims in a patent application, and issued a Patent Number 4472724, regarding the use of the papilloma pseudovirus.

13 Apr 2010